PuraPharm Corporation Limited reported unaudited consolidated financial results for the six months ended June 30, 2017. For the six months, Revenue was HKD 263,093,000 against HKD 212,249,000 reported a year ago. Profit before tax was HKD 13,787,000 against HKD 10,386,000 reported a year ago. Profit for the period attributable to owners of the parent was HKD 9,138,000 or 4.0 cents per diluted share against HKD 8,285,000 or 3.7 cents per diluted share reported a year ago. During the six months ended 30 June 2017, the total capital expenditure was HKD 40.5 million against HKD 35.1 million reported six months ended 30 June 2016.